ClinicalTrials.gg
RecruitingNCT07423390Updated Apr 30, 2026

Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy

A Phase 3 interventional study of Mecobalamin in Peripheral Neuropathy Due to Chemotherapy and Peripheral Neuropathy, Chemotherapy-induced, sponsored by Qinghai Red Cross Hospital. Recruiting at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Qinghai Red Cross Hospital · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
326
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Peripheral Nervous System Diseases with a site in China — 5 open to participants now, 5 under way, 1 of them phase 3. Peripheral Nervous System Diseases · China.

Planned enrollment
2nd of 14
326 · median 109
Started
2026
with 3 others
Phase 3
2 of 18
1 open now
Registered
15th of 18
by date
Lead sponsor
1 of 18
Qinghai Red Cross Hospital

Among the 18 studies in Peripheral Nervous System Diseases with a site in China, this one is the 2nd largest by planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2026, is one of 2 in phase 3, and was the 15th registered.

Peripheral Nervous System Diseases

476 studies on the registry are indexed under Peripheral Nervous System Diseases; 103 are open to participants now.

Browse Peripheral Nervous System Diseases studies →

Open to participants now

5 of the 18 studies in Peripheral Nervous System Diseases with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 65 Peripheral Nervous System Diseases studies recruiting now, 44 (68%) set no upper age limit and 10 (15%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Peripheral Nervous System Diseases with a site in China, or all of them as a file.
02

Study summary

Some patients receiving taxane-based chemotherapy experience numbness, tingling, or pain in their hands and feet, known as chemotherapy-induced peripheral neuropathy (CIPN). This study aims to find out whether oral mecobalamin can prevent or reduce CIPN. Participants will be assigned to take mecobalamin or to receive no routine mecobalamin prevention during chemotherapy, and outcomes will be compared between groups.

Read the detailed description

This is a prospective, multicenter, open-label randomized controlled trial to evaluate oral mecobalamin for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) in patients with solid tumors receiving taxane-based chemotherapy. Participants are assigned to receive prophylactic mecobalamin (0.5 mg orally three times daily, starting on the first day of taxane-based chemotherapy and continuing until chemotherapy completion) or no routine mecobalamin prophylaxis. The primary endpoint is the cumulative incidence of grade ≥2 CIPN (CTCAE v6.0) from randomization to the end of chemotherapy.

Secondary endpoints include measures of CIPN onset and severity, patient-reported outcomes (PROs), chemotherapy delivery, and safety. Study assessments are conducted at baseline and during each chemotherapy cycle.

03

Conditions studied

  • Peripheral Neuropathy Due to Chemotherapy
  • Peripheral Neuropathy, Chemotherapy-induced

Keywords

  • Chemotherapy induced peripheral neuropathy
  • Mecobalamin
  • Taxane
  • Prevention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed solid tumors, including but not limited to breast cancer, lung cancer, gastric cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and melanoma;
  2. Age ≥18 years;
  3. Scheduled to receive or neoadjuvant taxane-based chemotherapy (including paclitaxel, nab-paclitaxel, or docetaxel; as monotherapy or in combination) for early-stage disease, or has advanced disease with no prior chemotherapy;
  4. ≥3 months;
  5. performance status 0-2;
  6. Adequate major organ function (cardiac, hepatic, renal, and bone marrow function);
  7. Willing and able to provide written and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Severe impairment of major organ function such that the participant cannot tolerate standard-dose chemotherapy;
  2. Pre-existing peripheral neuropathy or a history of peripheral neuropathy;
  3. Skin conditions (e.g., severe palmoplantar keratoderma, active skin infection) that may interfere with assessment of CIPN symptoms;
  4. Recent use of medications that may alleviate CIPN symptoms;
  5. Inability to swallow, intestinal obstruction, or other conditions that may affect drug absorption;
  6. Known or allergy to mecobalamin;
  7. Pregnant or breastfeeding women.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
326 participants (estimated)

Study arms

  • Experimental
    Mecobalamin Prophylaxis

    Participants receive oral mecobalamin 0.5 mg three times daily (total 1.5 mg/day), starting on the first day of taxane chemotherapy and continuing until completion of chemotherapy. If CIPN-related symptoms (e.g., pain, paresthesia) occur, the treating physician will provide standard symptomatic treatment in accordance with current clinical guidelines.

    Drug: Mecobalamin

  • No intervention
    No Routine Mecobalamin Prophylaxis

    Participants do not receive routine mecobalamin prophylaxis. Follow-up schedule, education, and outcome assessments are the same as in the mecobalamin group. If CIPN-related symptoms (e.g., pain, paresthesia) occur, the treating physician will provide standard symptomatic treatment in accordance with current clinical guidelines.

Interventions

  • Oral mecobalamin tablets, 0.5 mg three times daily (total 1.5 mg/day), starting on Day 1 of taxane-based chemotherapy and continuing until completion of chemotherapy, administered as prophylaxis for chemotherapy-induced peripheral neuropathy. Participants in both groups are not permitted to use any other medications or supplements specifically for the prophylaxis of CIPN during the study period. However, if CIPN-related symptoms (e.g., pain, paresthesia) occur, the treating physician will provide standard symptomatic treatment in accordance with current clinical guidelines.

06

What researchers measure

Primary outcomes

  1. Cumulative incidence of grade ≥2 chemotherapy induced peripheral neuropathy (CIPN)

    Defined as the proportion of participants who experience grade ≥2 CIPN (assessed by CTCAE v6.0) at any time from randomization to the end of chemotherapy (or earlier discontinuation).

    Time frame: From randomization up to 24 weeks (maximum planned chemotherapy duration).

Secondary outcomes

  1. Cumulative incidence of any grade CIPN

    Defined as the proportion of participants who experience CIPN of any grade (assessed by CTCAE v6.0) at any time from randomization to the end of chemotherapy (or earlier discontinuation).

    Time frame: From randomization up to 24 weeks (maximum planned chemotherapy duration).

  2. Median time to first occurrence of grade ≥2 CIPN

    Defined as the median time from randomization to the first occurrence of grade ≥2 CIPN (assessed by CTCAE v6.0). Participants without grade ≥2 CIPN will be censored at the end of chemotherapy (or earlier discontinuation).

    Time frame: From randomization up to 24 weeks (maximum planned chemotherapy duration).

  3. Cumulative incidence of grade 2 CIPN

    Defined as the proportion of participants who experience grade 2 CIPN (assessed by CTCAE v6.0) at any time from randomization to the end of chemotherapy (or earlier discontinuation).

    Time frame: From randomization up to 24 weeks (maximum planned chemotherapy duration).

  4. Cumulative incidence of grade ≥3 CIPN

    Defined as the proportion of participants who experience grade ≥3 CIPN (assessed by CTCAE v6.0) at any time from randomization to the end of chemotherapy (or earlier discontinuation).

    Time frame: From randomization up to 24 weeks (maximum planned chemotherapy duration).

  5. Changes in EORTC QLQ-CIPN20 scores over time

    The European Organisation for Research and Treatment of Cancer Chemotherapy-Induced Peripheral Neuropathy 20-item questionnaire (EORTC QLQ-CIPN20) is a validated patient-reported outcome instrument assessing CIPN-related symptoms and functional impairment. It includes 20 items covering sensory, motor, and autonomic symptoms, each rated on a 4-point Likert scale. Raw scores are linearly transformed to 0 to 100 points according to the EORTC scoring manual; higher scores indicate worse symptom burden and functional limitations. The questionnaire will be administered at multiple time points to characterize the trajectory of CIPN during and after chemotherapy.

    Time frame: Baseline; during each chemotherapy cycle; end of chemotherapy (up to 24 weeks); and 1 week, 1 month, and 6 months after chemotherapy completion.

  6. Changes in EQ-5D-5L scores over time

    The EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) is a standardized instrument for measuring health-related quality of life. It consists of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each with five levels. EQ-5D-5L responses will be converted to a single utility index score using the China EQ-5D-5L value set (1 = full health; 0 = dead; values may be \< 0); higher index scores indicate better health. The EQ-5D-5L also includes a vertical visual analogue scale (VAS) ranging from 0 (worst imaginable health) to 100 (best imaginable health); higher VAS scores indicate better self-rated health. Both the index score and VAS score will be assessed at multiple time points to evaluate changes in health-related quality of life during and after chemotherapy.

    Time frame: Baseline; mid-treatment (at the midpoint of planned chemotherapy cycles, up to 12 weeks), end of chemotherapy (up to 24 weeks); and 1 week, 1 month, and 6 months after chemotherapy completion.

  7. Proportion of participants with taxane chemotherapy dose modification due to CIPN

    Defined as the proportion of participants who have taxane dose reduction, dose delay, or treatment discontinuation attributable to CIPN during the taxane chemotherapy period.

    Time frame: From randomization up to 24 weeks (maximum planned chemotherapy duration).

  8. Relative dose intensity (RDI) of taxane chemotherapy

    Defined as the relative dose intensity of taxane chemotherapy over the planned treatment period (actual dose intensity relative to the protocol/planned dose intensity), summarized for each participant.

    Time frame: From randomization up to 24 weeks (maximum planned chemotherapy duration).

  9. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

    Incidence and severity of AEs and SAEs occurring during the study.

    Time frame: From randomization through 6 months after chemotherapy completion.

Other outcomes

  1. Change in lower-limb sensory nerve conduction velocity (SNCV) assessed by nerve conduction studies (NCS)

    Change in lower-limb SNCV (m/s) assessed by NCS. NCS will be performed on the sural sensory nerve using standard surface stimulation and recording electrodes, following harmonized procedures across sites where NCS is performed. SNCV will be calculated from sensory nerve latency (ms) and the stimulation-to-recording distance; sensory nerve action potential (SNAP) amplitude (μV) and latency (ms) will also be recorded. Testing is optional and will be performed in a subset of participants at selected sites where NCS equipment and trained personnel are available.

    Time frame: Baseline and end of chemotherapy (up to 24 weeks).

07

Study locations

2 of 4 sites recruiting
  • Affiliated Hospital of Qinghai University
    Xining, Qinghai, China
    Not yet recruiting
  • Qinghai Red Cross Hospital
    Xining, Qinghai, China
    Recruiting
  • Affiliated Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital)
    Jinan, Shandong, China
    Not yet recruiting
  • Beijing Chaoyang Sanhuan Cancer Hospital
    Beijing, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) that underlie the results reported in publications will be shared with qualified researchers upon reasonable request. Shared IPD will include participant-level data on baseline characteristics, treatment exposure, primary and secondary outcome measures, and safety outcomes. Requests must include a scientifically sound research proposal and analysis plan. Access will be granted after approval by the study steering committee and completion of a data use agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning after publication of the primary results and available for 3 years.

Access criteria: De-identified IPD and supporting documents will be made available to qualified researchers upon submission of a scientifically valid research proposal to the corresponding author. Access requires approval by the study steering committee and the completion of a data use agreement to ensure appropriate data use and participant confidentiality.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Mar 2029, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 20, 2026
StartActual
Feb 24, 2026
Primary completionEst.
Mar 30, 2029
CompletionEst.
May 31, 2029
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07423390
Lead sponsor
Qinghai Red Cross Hospital
Responsible party
Dongqiuxia (Clinical Professor, Qinghai Red Cross Hospital) — Principal investigator
First posted
Feb 20, 2026
Start date
Feb 24, 2026
Primary completion
Mar 30, 2029 (estimated)
Completion
May 31, 2029 (estimated)
Last update
Apr 30, 2026

Study contacts

Jiuda Zhao, Dr
Contact
jiudazhao@126.com
869716230893

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mecobalamin

Start the discussion